Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
14.25
-0.48 (-3.26%)
Jan 8, 2025, 4:00 PM EST - Market closed

Company Description

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.

Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.

It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.

Palvella Therapeutics, Inc.
Country United States
Founded 2015
CEO Wesley Kaupinen

Contact Details

Address:
125 Strafford Avenue, Suite 360
Wayne, Pennsylvania 19087
United States
Phone 484 253 1461
Website palvellatx.com

Stock Details

Ticker Symbol PVLA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001742961
Employer ID 81-2228053
SIC Code 2834

Key Executives

Name Position
Wesley Kaupinen Chief Executive Officer
Matthew Korenberg Chief Financial Officer
Kathleen Goin Chief Operating Officer

Latest SEC Filings

Date Type Title
Dec 30, 2022 D Notice of Exempt Offering of Securities
Jun 3, 2020 D Notice of Exempt Offering of Securities
Aug 12, 2019 D/A Filing
Apr 12, 2019 D Notice of Exempt Offering of Securities
Jun 14, 2018 D Notice of Exempt Offering of Securities